Xilonix: Phase III ongoing

XBiotech said an IDMC recommended continuation of the double-blind, placebo-controlled, U.S. Phase III XCITE trial evaluating IV Xilonix every 2 weeks plus best supportive care (BSC). The committee met following enrollment of 400 patients of a planned 800 patients. Another IDMC meeting is scheduled once the trial enrolls 600 patients or when the trial meets its first efficacy analysis milestone. ...